– USA, MA – Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced the appointment of Jeff Albers to its Board of Directors as Chair alongside Dr. Allison Luo (M.D.) also joining the Board.
About Jeff Albers
Jeff Albers is an accomplished leader with over 25 years in the biopharmaceutical industry. As the former CEO of Blueprint Medicines, he scaled the company from a research-stage organization to a global precision medicine leader. Jeff was responsible for two U.S. Food and Drug Administration approvals. Jeff currently is board chair of Blueprint Medicines and on the board of directors at Kymera Therapeutics and Spyre Therapeutics.
“I am honored to assume the role of Board Chair at Triveni and to work alongside this committed team,” said Albers. “Triveni is backed by a syndicate of top tier investors who share the company’s vision to advance novel I&I therapies based on human genetics, best-in-class antibody design, and precision medicine.”
Jeff Albers earned a B.S. from Indiana University as well as an M.B.A. and J.D. from Georgetown University.
About Allison Luo
Allison Luo has over two decades of clinical development expertise in the biopharmaceutical industry – most recently serving as CMO of Prometheus Biosciences. Dr. Luo was previously CMO of Escalier and Oppilan (Ventyx), SVP of Clinical Development for Gastroenterology at Progenity (Biora), and VP of Clinical Development at Ophthotech (Iveric Bio), where she completed two Phase 3 studies. She also worked at Bristol Myers Squibb, overseeing programs for Orencia® and eldelumab.
“This is an exciting opportunity to be part of a precision medicines company. We know that the probability of success in drugging a target is higher when genetic linkage is present,” said Dr. Luo. “TRIV-509 has the potential to be a best- and first-in class therapy for atopic dermatitis via its unique mechanism that directly impacts barrier dysfunction, inflammation, and itch as well as for other indications.”
Dr. Allison Luo earned a B.S. in biochemistry and an M.D. from Northwestern University, followed by a fellowship in drug development at Abbott Laboratories (AbbVie).
About Triveni Bio
Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact.
For more information https://triveni.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.